Molecular Templates. has been granted a patent for Shiga toxin effector polypeptides with reduced immunogenicity. These polypeptides can be used in therapeutics, diagnostics, and immunization, targeting specific cell types for treating diseases like cancers and infections, while minimizing immune responses. GlobalData’s report on Molecular Templates gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Molecular Templates, Peptide pharmacophores was a key innovation area identified from patents. Molecular Templates's grant share as of July 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Shiga toxin effector polypeptides for targeted therapeutics
The granted patent US12065469B2 describes a novel cell-targeting molecule that integrates a protein component designed for specific binding to extracellular target biomolecules on cell surfaces, excluding CD38. The molecule features a Shiga toxin effector polypeptide with an amino acid sequence exhibiting at least 90% identity to a specified sequence (SEQ ID NO: 1). This sequence includes at least four endogenous B-cell epitope regions, with several modified regions containing specific amino acid substitutions. Notably, the molecule is characterized by particular amino acid residues at designated positions, which are critical for its functionality. The claims also detail the potential for the binding region to be fused to the Shiga toxin effector polypeptide, forming a continuous polypeptide structure.
Additionally, the patent outlines various configurations for the binding region, which may include immunoglobulin-type structures and a range of polypeptide forms such as single-domain antibodies and bispecific minibodies. The binding region can also incorporate a linker peptide, enhancing the molecule's stability and functionality. The patent further encompasses pharmaceutical compositions that utilize this cell-targeting molecule in conjunction with acceptable excipients or carriers, indicating its potential application in therapeutic contexts. Overall, the claims present a comprehensive framework for a targeted therapeutic agent that could be significant in medical treatments involving cell-specific interactions.
To know more about GlobalData’s detailed insights on Molecular Templates, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
